[{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Axis Clinicals Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"15","companyTruncated":"Acrotech Biopharma \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acrotech Biopharma \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Axis Clinicals Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"15","companyTruncated":"Acrotech Biopharma \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Clinipace Worldwide | Beckloff Associates, Inc. | Kansas City Bioanalytical Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Clinipace Worldwide | Beckloff Associates, Inc. | Kansas City Bioanalytical Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Acrotech Biopharma \/ Clinipace Worldwide | Beckloff Associates, Inc. | Kansas City Bioanalytical Laboratories"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Onxeo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Acrotech Biopharma","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Acrotech Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Acrotech Biopharma \/ Acrotech Biopharma"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Axis Clinicals Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acrotech Biopharma \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Axis Clinicals Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acrotech Biopharma \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Axis Clinicals Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acrotech Biopharma \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase III","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase III","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Valerio Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ Valerio Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Acrotech Biopharma \/ Valerio Therapeutics"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sodium Levofolinate","moa":"Serine hydroxymethyltransferase","graph1":"Oncology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ National Cancer Institute"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Axis Clinicals Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Hematology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Axis Clinicals Ltd."}]
Find Clinical Drug Pipeline Developments & Deals by Acrotech Biopharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
